GeneDx Holdings drops 49% as class action targets Fabric Genomics write-off

GeneDx Holdings Corp. faces a securities class action after its stock lost $33.42, or 49%, on May 5, 2026, following a disastrous first-quarter earnings report that revealed a 94% impairment charge on its Fabric Genomics acquisition.

"The company may have intentionally or recklessly misled investors about Fabric's real value to the company," Reed Kathrein, partner at Hagens Berman leading the firm's investigation, said.

The lawsuit, filed by Bronstein, Gewirtz & Grossman and Hagens Berman, covers investors who bought GeneDx common stock between April 16, 2025 and May 4, 2026. GeneDx reported a tenfold increase in net loss for Q1 2026, with Fabric Genomics contributing a $2.5 million revenue miss and $31.2 million in impairment charges — roughly 94% of the $33.2 million cash purchase price paid just one year earlier. The company's average reimbursement rate fell about $200 short of the flat guidance management gave in February, which the company blamed on an adverse product mix shift toward genome testing, whose ARR was half that of exome. GeneDx also cut its 2026 revenue guidance by 12% and lowered its exome and genome revenue growth forecast to "at least 20%" from the 33% to 35% range previously communicated.

The class action alleges GeneDx made false statements about the durability of its average reimbursement rates, the importance of Fabric Genomics to its business model, and the sustainability of its gross margins. Investors have until Aug. 3, 2026, to petition the court for lead plaintiff status. The 49% single-day decline erased more than $1 billion in market value, according to the complaint, and the stock has not recovered. The next catalyst for the case is the lead plaintiff deadline, after which the court will consolidate claims and schedule the first procedural hearing.

This article is for informational purposes only and does not constitute investment advice.